Theratechnologies Inc T.TH

Dual approach of Tesamorelin…

[scarlet1967]

To our knowledge, this is the first study to employ a dual transcriptomic and proteomic approach to identify novel circulating protein signatures and therapeutic targets for NAFLD in PLWH. In addition, these results are demonstrated in a randomized trial with the presence of a placebo comparator group, and the availability of detailed phenotypic data on study participants. 

 

https://www.nature.com/articles/s41598-021-89966-y

[scarlet1967]

The article published today, it would be great to add a science section to the website adding these studies to it. "In this study, we found that tesamorelin decreased plasma levels of VEGFA relative to placebo. Moreover, tesamorelin-treated participants who had the largest reduction in VEGFA demonstrated the greatest decline in NAS score. Angiogenesis plays a pivotal role in the

[qwerty22]

Grinspoon and his colleagues are just so productive, this reads great. Makes me wonder how much of all this they can incorporate into the Ph3.

[qwerty22]

It also makes me wondevjust how important it is/was for THTX to allow these guys to get all these studies done. I still think there is something of a leap of faith in where an F2/F3 population lands with the Ph3 biopsy endpoints but this data talks to that, it's sooooo directional. It's almost there. The liver WILL get healthier if you take Tesamorelin. How much though? Enough to get

[scarlet1967]

Some details from this study so they are explaining the proteomic (studying proteins) and transcriptomic (studying molecules expressed from the genes) effect of tesamorelin a dual approach for the treatment of NAFL/NASH. Nothing new but they sum it up nicely and tied some loose ends (totality of data). I like the fact that they mentioned innovative treatment few times.   “Tesamorelin

[Bucknelly21]

can someone break it down for us non science people 

[scarlet1967]

Tesamorelin has inhibiting effects on pro inflammatory proteins responsible for liver inflammation/fibrosis.

[SPCEO1]

I would think any time one of your drugs is featured in a Nature article, that it would be worthy of a press release. I assume you don't get your article published in Nature unless you really have something noteworthy in the article. Can anyone think why TH would not draw attention to this article? 

[scarlet1967]

My best guess is Leah was busy preparing Montreal-style smoked meat as the entire IR department having their daily picnic at Mount Royal Park?

[SABBOBCAT]

HAHAHA It is comments like this that keep me from going completely insane as a TH investor.  I would say another ball dropped, but it is starting to feel like the ball has been dropped for some time, and whenever we think TH is going to pick it up they end up kicking it down the road further. 

[scarlet1967]

No worries mate after I negotiate a group discount for entire THTX's board excluding Paul to get admitted to a reputable rehabilitation facility  I am sure I can squeeze more discounts fot posters here.

[qwerty22]

It's published in a journal called Scientific Reports which is from the same publishers as Nature but a different journal. I would say it's still a solid journal though.

[qwerty22]

They show for some or all of the 3 protein biomarkers that :- 1) These biomarkers are increased in their hiv NAFLD/NASH patients. It is already known these proteins play some role in Nafld/Nash, inflammation, fibrosis and/or activation of disease inducing cells 2) That the amount of these proteins correlates with the severity of disease (more disease, more protein : less disease less protein)

[scarlet1967]

Using biomakers as diagnostic tools is where the industry is heading. https://www.dovepress.com/serum-micro-rna-122-level-as-a-simple-noninvasive-marker-of-mafld-seve-peer-reviewed-fulltext-article-DMSO